# Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine

> **NCT02366013** · PHASE1 · COMPLETED · sponsor: **International AIDS Vaccine Initiative** · enrollment: 22 (actual)

## Conditions studied

- HIV

## Interventions

- **BIOLOGICAL:** rcAd26.MOS1.HIV-Env 1x10^8 vp
- **BIOLOGICAL:** rcAd26.MOS1.HIV-Env 1x10^9 vp
- **BIOLOGICAL:** rcAd26.MOS1.HIV-Env 1x10^10 vp
- **BIOLOGICAL:** rcAd26.MOS1.HIV-Env 1x10^11 vp

## Key facts

- **NCT ID:** NCT02366013
- **Lead sponsor:** International AIDS Vaccine Initiative
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2016-11-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02366013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02366013, "Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02366013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*